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The inappropriate expansion of self-reactive ‘‘bystander’’ T cells can contribute to autoimmune disease. In
this issue of Immunity, Watanabe et al. (2014) demonstrate that the tumor suppressor p53 prevents the cyto-
kine-dependent proliferation of T cells in the absence of cognate antigens.The hallmark of an adaptive immune
response is the activation and clonal
expansion of antigen-specific T and B
lymphocytes. The recruitment of a T cell
into an immune response requires the
coordinated delivery of three distinct
signals. Signal 1 is delivered when the
T cell receptor (TCR) engages cognate
antigenic peptides presented by major
histocompatibility complexes (MHC) dis-
played on the surface of an antigen-pre-
senting cell (APC). Signal 2 is delivered
upon the recognition of costimulatory
ligands presented by APCs that have
been exposed to proinflammatory stimuli.
Lastly, signal 3 is delivered by combina-
tions of cytokines that support the sur-
vival, proliferation, effector function, and
differentiation of T cells that have received
signals 1 and 2. In particular, cytokines
that signal through the common gamma
chain, such as interleukin-2 (IL-2),
contribute to signal 3 by promoting the
survival and expansion of T cells. This
system is exquisitely selective, and for
the most part ensures that nonspecific
‘‘bystander’’ lymphocytes do not partici-
pate in immune responses. The effective-
ness of this safety mechanism is remark-
able, given that the vast majority of the
T cells present in secondary lymphoid or-
gans are not specific for antigens derived
from the offending pathogen and that
many of these cells are capable of recog-
nizing self-antigens. These potentially
hazardous cells are exposed to the
same milieu of costimulatory ligands and
cytokines available to neighboring anti-
gen-specific T cells. Consequently, the
mechanisms that prevent the inappro-
priate expansion of bystander T cells
might contribute to the avoidance of
autoimmune disorders. In this issue of
Immunity, Watanabe et al. (2014) provide
insight into this process by demonstratingthat the tumor suppressor p53 (TP53 in
human; Trp53 in mouse) imposes the
checkpoint that prevents the proliferation
of bystander T cells exposed to signal 3,
in the form of IL-2, and that this check-
point is lifted by signals delivered through
the TCR.
A tremendous amount of study has
been devoted to the roles of p53 in cancer
because most human cancers involve
either inactivating mutations in p53 itself
or in components of the p53 pathway
(Green and Kroemer, 2009). Given the
importance of p53 in cancer biology, it is
somewhat surprising that so little is
known about its functions in T cells. The
best characterized role of p53 is that
of a transcription factor that either halts
the cell cycle or induces apoptotic cell
death in response to DNA damage.
Consequently, several earlier studies
have addressed the roles of p53 in T cell
development, during the recombination
of genomic TCR loci. Consistent with its
roles in cancer biology, p53 contributes
to the suppression of thymocyte prolife-
ration during the checkpoint associated
with the recombination of the TCRb locus
and the subsequent formation of a func-
tional pre-TCR. This process requires
the introduction of double-strand DNA
breaks and is expected to activate p53.
Remarkably, the loss of p53 is sufficient
to permit thymocytes that are incapable
of generating a functional pre-TCR to
progress from the coreceptor ‘‘double-
negative’’ (DN) stage to the CD4+ CD8+
‘‘double-positive’’ (DP) stage (Guidos
et al. 1996; Haks et al. 1999). B cell devel-
opment is similarly restored in recombi-
nase-deficient mice lacking p53. The
ability of activated B cells to undergo
cycles of expansion and somatic hyper-
mutation is also influenced by p53.
In particular, BCL6, a transcriptionalImmunityrepressor that is a hallmark of germinal
center B cells, attenuates Trp53 transcrip-
tion (Phan and Dalla-Favera, 2004). Thus,
these B cells are able to evade the cyto-
static and proapoptotic effects that would
normally be triggered by p53 in response
to the mutations induced during somatic
hypermutation by the activation-induced
cytidine deaminase, AID.
In the current study, Watanabe et al.
demonstrate that IL-2 signaling alone
directed the upregulation of p53 and
inhibited T cell proliferation and that the
genetic ablation of Trp53 enabled the
spontaneous proliferation of naive T cells
exposed to IL-2 in the absence of antigen.
They further showed that although stimu-
lation via the TCR rapidly increases the
amount of p53 protein, antigenic stimula-
tion ultimately reduced the amounts of
p53 protein and mRNA, thereby enabling
proliferation in response to IL-2 (Figure 1).
Watanabe et al. proceeded to confirm
these observations in vivo by using TCR
transgenic T cells in an adoptive-transfer
model. In sum, their observations indicate
that p53 imposes the checkpoint that
prohibits the expansion of T cell clones
in the absence of antigenic stimuli.
Because the activation of naive CD4+
T cells in the periphery is not associated
with directed DNA rearrangement or mu-
tation, it is not immediately obvious why
p53 should have evolved to enforce this
checkpoint. However, the transient upre-
gulation of p53 following TCR ligation
might serve a practical purpose. In many
long-lived vertebrates, thymic involution
significantly reduces the output of naive
T cells in the adult, increasing the average
age of the naive T cell pool. In humans,
peripheral naive T cells can survive 6–10
years, providing ample opportunity for
the accumulation of DNA damage (den
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Figure 1. The Tumor Suppressor p53 Blocks Bystander T Cell Proliferation Triggered by IL-2
(upper left) In response to a pathogenic challenge, CD4+ T cells that are not specific for antigen are
exposed to mitogenic cytokines such as IL-2. In normal animals, IL-2-dependent signals increase the
abundance of p53 protein, blocking the proliferation of these ‘‘bystander’’ T cells.
(upper right) T cells that lack functional p53 proliferate when exposed to IL-2, even in the absence of TCR
signaling, confirming the essential role of p53 in the enforcement of this checkpoint.
(bottom right) The specific recognition of antigen (pMHC) by the TCR increases the concentration of the
mRNA encoding Mdm2, a ubiquitin ligase that targets p53 for proteasomal degradation. The ensuing
degradation of p53 enables the expansion of antigen-specific T cell clones while ensuring that potentially
self-reactive ‘‘bystander’’ cells do not participate in the immune response.
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PreviewsThe transient induction of p53 following
TCR ligation might delay the initiation of
cell cycle to allow the resolution of this
DNA damage. This mechanism is likely
to play an important role in limiting the
initiation of T cell lymphoma. It will be
interesting to determine whether other
cytokines that signal through the common
gamma chain also increase the abun-
dance of p53 expression. In particular,
IL-7 promotes thymocyte survival and
expansion prior to the checkpoints asso-
ciated with the formation of a viable pre-
TCR (Xiong et al. 2013; Singer et al.
2008). A logical extension of the current
study would be to examine whether IL-7
terminates its role in thymocyte expan-
sion by inducing p53 and whether
signaling through newly formed pre-TCR
complexes lifts the resulting develop-
mental blockade.
Another prospect raised by this study
is the possibility that the autoimmune
disease observed in T cell-specific condi-634 Immunity 40, May 15, 2014 ª2014 Elsevitional Trp53 knockout animals might
be caused, at least in part, by the
inappropriate activation of self-reactive
bystander T cells. Although the study
that initially reported this autoimmune dis-
order (Kawashima et al. 2013) attributed
the disease to a reduction in the numbers
of regulatory T (Treg) cells, the few Treg
cells observed in these animals are fully
functional. It will be interesting to deter-
mine the extent to which each of these
mechanisms contributes to the observed
autoimmune pathology.
The authors also investigated the
mechanism by which the amount of p53
is reduced following antigenic stimulation.
They discovered that the abundance of
the mRNA encoding Mdm2, a negative
regulator of p53, is upregulated in cells
exposed to cognate antigen-bearing
APCs, but is unperturbed in cells exposed
to IL-2 alone. Mdm2 is an E3 ubiquitin
ligase that binds to and inhibits the tran-
scriptional functions of p53, and that caner Inc.mark p53 for proteasomal degradation
(Figure 1; Kruse and Gu, 2009). To deter-
mine whether Mdm2 is responsible for
the TCR-induced decrease in p53 abun-
dance and for subsequent CD4+ T cell
proliferation, Watanabe et al. used the
small-molecule inhibitor Nutlin3a, which
blocks the interaction between Mdm2
and p53 and leads to p53 stabilization
and transcriptional activation. They found
that the treatment of antigen-stimulated
cells with Nutlin3a increased the abun-
dance of p53 and abolished the prolife-
ration of these cells. Although Nutlin3a
also blocks the interaction of Mdm2 with
the p53 family members p73 and p63,
Nutlin3a did not have a significant effect
on the proliferation of p53-deficient cells,
indicating that p53 is the critical inhibitor
of proliferation in this system.
Perhaps the most exciting aspect of
the current study is that it opens up
numerous avenues of research. Both p53
and Mdm2 are central points in complex
webs of intersecting pathways. For
example, the amount of p53 increased in
the first 48 hr following antigen plus IL-2
stimulation, despite the fact that there
was no increase in the abundance of
the Trp53 mRNA. This clearly suggests
some form of translational or posttrans-
lational control. Future studies will need
to determine the precise mechanisms
by which p53 is stabilized by cytokine
stimulation, as well as which downstream
targets of p53 are responsible for block-
ing proliferation in cells exposed to IL-2
alone. Another question left unaddressed
concerns the relative roles of TCR sig-
naling and costimulatory signaling in
the upregulation of Mdm2. Nevertheless,
the study presented by Watanabe et al.
has provided crucial insight into a pre-
viously unappreciated mechanism that
suppresses the proliferation of bystander
CD4+ T cells during adaptive immune
responses. It will be important to further
clarify howp53 influencesTcell activation,
the initiation of autoimmunity, and the for-
mation of T cell lymphomas. Perhaps this
study will lift the checkpoint that has thus
far limited the recruitment of ‘‘bystander’’
immunologists into studies of p53.
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Reprogramming cellular metabolism helps support T cell growth and effector function upon activation. In this
issue of Immunity, Nakaya et al. (2014) report that the glutamine transporter ASCT2 regulates T cell meta-
bolism and mTOR kinase signaling to shape inflammatory T helper cell responses.T lymphocytes are central effectors of
the adaptive immune system, and their
proper function is critical to mediate
long-lasting immunity to foreign patho-
gens. Upon activation by antigens, naive
CD4+ T cells expand and differentiate
into specific T helper (Th) cell populations,
including Th1, Th2, and Th17 cells, each
with specific effector functions tailored
toward the given pathogen. Although
proinflammatory Th responses are impor-
tant for mediating immunity to foreign
pathogens, unchecked or misdirected
Th cell responses can also promote
inflammation and autoimmunity. One of
the fundamental programs that helpsdrive
T cell activation is the regulation of cellular
metabolism, the series of biochemical
reactions that mediate cellular energy
production and biosynthesis. The pre-
dominant metabolic program of activated
CD4+ Th cells is a shift to aerobic glycol-
ysis (also known as the ‘‘Warburg Effect’’),
a progrowth metabolic program that
generates both ATP and macromolecules
required for T cell proliferation (MacIver
et al., 2013). Amino acids (AAs) are also
key nutrients for T cells, because they
can serve as both a fuel source and
a pool of biosynthetic precursors for
protein and nucleic acid biosynthesis. Of
particular relevance to T cell biology is
the nonessential amino acid (NEAA) gluta-mine, which is rapidly taken up by T cells
upon activation (Carr et al., 2010; Wang
et al., 2011). However, the importance
of glutamine to CD4+ T cell-mediated
immune responses in vivo has been diffi-
cult to study. Here, Nakaya et al. (2014)
demonstrate that the alanine, serine,
and cysteine (ASC) system AA trans-
porter 2 (ASCT2) is a key regulator
of glutamine uptake in CD4+ Th cells and
influences the development of proinflam-
matory Th1 and Th17 responses in vitro
and in vivo.
ASCT2 is a sodium-dependent, neutral
amino acid transporter encoded by
SLC1A5 that mediates the cotransport of
Na+ along with glutamine (or other neutral
AAs such as alanine, cysteine, serine,
and threonine) with high affinity (Figure 1).
However, in addition to ASCT2, there are
a number of AA transporters expressed
by activated T cells, including the so-
dium-coupled neutral AA transporters
SNAT1 and SNAT2 (Carr et al., 2010; Sin-
clair et al., 2013), which are capable of
transporting glutamine. By using gene-
targeted mice lacking ASCT2 expression
(Asct2/ mice), Nakaya et al. (2014)
demonstrated that glutamine uptake
by T cells, both short-term (30 min) and
long-term (>20 hr) postactivation, were
markedly reduced in CD4+ T cells from
Asct2/ mice. These data indicate thatASCT2 is a major regulator of glutamine
transport in T lymphocytes. Activated
Asct2/ T cells also displayed reduced
rates of glucose uptake, lactate produc-
tion (an indicator of aerobic glycolysis),
and oxygen consumption (a mea-
surement of oxidative phosphorylation
[OXPHOS]), suggesting that themetabolic
program normally triggered by TCR stim-
ulation was attenuated in T cells lacking
ASCT2. The authors attributed these ob-
servations to reduced expression of the
glucose transporter Glut1 and transcrip-
tion factor c-Myc, both key components
of metabolic reprogramming in T cells
(MacIver et al., 2013), in Asct2/ T cells.
Addition of exogenous glutamine restored
the glycolytic defect of ASCT2-deficient
T cells, suggesting that glutamine avail-
ability can directly impact other metabolic
programs required for T cell proliferation.
Mechanistically, the authors identified
the CARMA1-BCL10-MALT1 (CBM) sig-
nalosome, a signaling complex that acti-
vates nuclear factor-kB (NF-kB) signaling
downstream of the TCR (Thome, 2004), as
a regulator of TCR-mediated glutamine
uptake and ASCT2 expression in T cells
(Figure 1). Regulation of glutamine uptake
by the CBM complex appeared to be
independent from CBM-dependent NF-
kB activation, as IKKb-deficient T cells
displayed no impairment in glutamine40, May 15, 2014 ª2014 Elsevier Inc. 635
